Semliki Forest virus E2 envelope epitopes induce a nonneutralizing humoral response which protects mice against lethal challenge - PubMed (original) (raw)
Semliki Forest virus E2 envelope epitopes induce a nonneutralizing humoral response which protects mice against lethal challenge
H Grosfeld et al. J Virol. 1989 Aug.
Abstract
Along the 422 amino acids of the Semliki Forest virus (SFV) E2 envelope glycoprotein, we identified 13 peptide cassettes (ranging in size from 15 to 25 amino acids and designated A through N) that contain hydrophilic sequences flanked by amino acid sequences conserved in the E2 envelopes of the alphavirus family. Six peptide blocks containing either a single cassette or two to three contiguous cassettes (A, BC, DE, FG, HIK, and LMN) were produced in Escherichia coli as recombinant proteins fused to the N terminus of beta-galactosidase. All of the SFV E2 recombinant polypeptides except A-beta-galactosidase were recognized on Western blots (immunoblots) by anti-SFV polyclonal antisera. In addition, these five recombinant proteins induced in mice antibodies that interacted specifically with SFV E2 protein on Western blots as well as with the intact virions in an enzyme-linked immunosorbent assay. The six hybrid proteins were used to vaccinate mice and were tested for the ability to confer resistance against lethal doses of SFV. Peptides BC and HIK, located at amino acid positions 114 to 149 and 216 to 288, respectively, of E2, protected partially (40 to 60%) against SFV challenge. A third peptide, LMN, located between amino acid positions 289 and 352, rendered mice totally resistant to an SFV challenge of 250 50% lethal doses. The partially protective effects of the BC and HIK cassettes and the high efficacy of the LMN cassette were consistently demonstrated, independent of the adjuvant (complete Freund or alum), immunization protocol, and strain of mice used. None of the antisera raised against any given cassette could neutralize the virus in an in vitro tissue culture assay or in a plaque reduction neutralization test. Nevertheless, passive transfer experiments demonstrated that in the case of LMN, the protective effect was mainly of a humoral nature.
Similar articles
- Divergent envelope E2 alphavirus sequences spanning amino acids 297 to 352 induce in mice virus-specific protective immunity and antibodies with complement-mediated cytolytic activity.
Grosfeld H, Lustig S, Gozes Y, Velan B, Cohen S, Leitner M, Lachmi B, Katz D, Olshevski U, Shafferman A. Grosfeld H, et al. J Virol. 1992 Feb;66(2):1084-90. doi: 10.1128/JVI.66.2.1084-1090.1992. J Virol. 1992. PMID: 1309890 Free PMC article. - Delineation of protective epitopes on the E2-envelope glycoprotein of Semliki Forest virus.
Grosfeld H, Velan B, Leitner M, Lustig S, Lachi BE, Cohen S, Shafferman A. Grosfeld H, et al. Vaccine. 1991 Jun;9(6):451-6. doi: 10.1016/0264-410x(91)90134-r. Vaccine. 1991. PMID: 1716035 - Identification of linear epitopes on Semliki Forest virus E2 membrane protein and their effectiveness as a synthetic peptide vaccine.
Snijders A, Benaissa-Trouw BJ, Oosterlaken TA, Puijk WC, Posthumus WP, Meloen RH, Boere WA, Oosting JD, Kraaijeveld CA, Snippe H. Snijders A, et al. J Gen Virol. 1991 Mar;72 ( Pt 3):557-65. doi: 10.1099/0022-1317-72-3-557. J Gen Virol. 1991. PMID: 1706409 - A delayed-type hypersensitivity-inducing T-cell epitope of Semliki Forest virus mediates effective T-helper activity for antibody production.
Snijders A, Benaissa-Trouw BJ, Visser-Vernooy HJ, Fernandez I, Snippe H, Kraaijeveld CA. Snijders A, et al. Immunology. 1992 Nov;77(3):322-9. Immunology. 1992. PMID: 1282493 Free PMC article. - Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus.
Fernández IM, Snijders A, Benaissa-Trouw BJ, Harmsen M, Snippe H, Kraaijeveld CA. Fernández IM, et al. J Virol. 1993 Oct;67(10):5843-8. doi: 10.1128/JVI.67.10.5843-5848.1993. J Virol. 1993. PMID: 7690411 Free PMC article.
Cited by
- Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen.
Grosfeld H, Cohen S, Bino T, Flashner Y, Ber R, Mamroud E, Kronman C, Shafferman A, Velan B. Grosfeld H, et al. Infect Immun. 2003 Jan;71(1):374-83. doi: 10.1128/IAI.71.1.374-383.2003. Infect Immun. 2003. PMID: 12496187 Free PMC article. - Protective immunity of Hantaan virus nucleocapsid and envelope protein studied using baculovirus-expressed proteins.
Yoshimatsu K, Yoo YC, Yoshida R, Ishihara C, Azuma I, Arikawa J. Yoshimatsu K, et al. Arch Virol. 1993;130(3-4):365-76. doi: 10.1007/BF01309667. Arch Virol. 1993. PMID: 8517793 - A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice.
Weger-Lucarelli J, Chu H, Aliota MT, Partidos CD, Osorio JE. Weger-Lucarelli J, et al. PLoS Negl Trop Dis. 2014 Jul 24;8(7):e2970. doi: 10.1371/journal.pntd.0002970. eCollection 2014 Jul. PLoS Negl Trop Dis. 2014. PMID: 25058320 Free PMC article. - Mapping of viral epitopes with prokaryotic expression products.
Lenstra JA, Kusters JG, van der Zeijst BA. Lenstra JA, et al. Arch Virol. 1990;110(1-2):1-24. doi: 10.1007/BF01310699. Arch Virol. 1990. PMID: 1689994 Free PMC article. Review. - Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax.
Cohen S, Mendelson I, Altboum Z, Kobiler D, Elhanany E, Bino T, Leitner M, Inbar I, Rosenberg H, Gozes Y, Barak R, Fisher M, Kronman C, Velan B, Shafferman A. Cohen S, et al. Infect Immun. 2000 Aug;68(8):4549-58. doi: 10.1128/IAI.68.8.4549-4558.2000. Infect Immun. 2000. PMID: 10899854 Free PMC article.
References
- J Gen Virol. 1986 Feb;67 ( Pt 2):229-34 - PubMed
- J Virol. 1984 Nov;52(2):575-82 - PubMed
- Virology. 1976 Jan;69(1):93-103 - PubMed
- J Biol Chem. 1980 Jan 10;255(1):168-74 - PubMed
- Nature. 1980 Nov 20;288(5788):236-41 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials